Olmesartan Medoxomil

[{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$310.0 million","newsHeadline":"Roche Enters Partnership with Alnylam to Co-Develop and Co-Commercialise RNAi Therapeutic Zilebesiran to Treat Hypertension in Patients with High Cardiovascular Risk","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Receives Final Approval from The USFDA for Olmesartan Medoxomil and Hydrochlorothiazide Tablets","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche and Alnylam Report Positive Topline Results from The Phase II Kardia-2 Study in People with Hypertension, Demonstrating Clinically Significant Blood Pressure Reductions with Zilebesiran when Added to Standard of Care","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II"}]

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

110 Suppliers, 45 USDMF, 38 CEP/COS, 18 JDMF, 32 EU WC, 43 KDMF, 22 NDC API, 60 Listed Suppliers

DEVELOPMENTS

5 Drug(s) in Development

5 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

36 Suppliers

36 Suppliers

DOSSIERs // Finished Dosage Forms

653 Dossiers, 185 FDA Orange Book, 201 Europe, 51 Canada, 57 Australia, 159 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 20MG, TABLET;ORAL - 40MG, TABLET;ORAL - 5MG, TABLET;ORAL - 12.5MG;20MG, TABLET;ORAL - 12.5MG;40MG, TABLET;ORAL - 25MG;40MG, TABLET;ORAL - EQ 10MG BASE;20MG, TABLET;ORAL - EQ 10MG BASE;40MG, TABLET;ORAL - EQ 5MG BASE;20MG, TABLET;ORAL - EQ 5MG BASE;40MG

RELATED EXCIPIENT COMPANIES

Suppliers, 38 Kerry, 21 Roquette, 21 BASF, 16 Microlex e.U, 12 Sigachi Industries, 11 Corel Pharma Chem, 9 Seppic, 9 Gangwal Healthcare, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 7 DFE Pharma, 7 Gangwal Chemicals, 7 Ideal Cures Pvt Ltd, 6 Nanjing Well Pharmaceutical, 6 Lonza Capsugel, 6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 4 Kima Chemical, 4 SPI Pharma, 4 Prachin Chemical, 4 Vasa Pharmachem, 4 Ingredion Pharma Solutions, 3 The Dow Chemical Company, 3 Clariant, 3 Actylis, 2 Pharmatrans-Sanaq, 2 Boai NKY Pharmaceuticals Ltd, 2 Seqens, 2 Nomisma Healthcare, 1 Rochem International Inc, 1 Aeon Procare, 1 DKSH, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Alcedo Pharmachem, 1 Finar, 1 Avesta Pharma, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Ulanqab Kema New Material, 1 Jai Radhe Sales, 1 ACG Worldwide, 1 Qualicaps

EXCIPIENTS BY APPLICATIONS

66 Fillers, Diluents & Binders, 53 Coating Systems & Additives, 33 Disintegrants & Superdisintegrants, 31 Controlled & Modified Release, 30 Direct Compression, 25 Lubricants & Glidants, 24 Thickeners and Stabilizers, 22 Granulation, 18 Topical, 16 Film Formers & Plasticizers, 14 Solubilizers, 13 Co-Processed Excipients, 10 Parenteral, 9 Taste Masking, 6 Chewable & Orodispersible Aids, 6 API Stability Enhancers, 6 Emulsifying Agents, 6 Rheology Modifiers, 5 Empty Capsules, 4 Vegetarian Capsules, 3 Surfactant & Foaming Agents, 2 Coloring Agents

GLOBAL SALES INFORMATION

24 US Medicaid Prescriptions, 187 Finished Drug Prices

MARKET PLACE

30 APIs, 7 DOSSIERS // FDF, 1 Intermediates

PATENTS

3 Health Canada Patents

3 Health Canada Patents

ANALYTICAL SOLUTION(s)

2 BioAnalytical Methods, 2 EDQM Standards, 2 USP Standards, 4 JP Standards, 8 Other Ref. Standards

DIGITAL CONTENT

3 Data Compilation & Company Tracker #PharmaFlow, 91 News

All Data

Developments

Filters

FILTER:

Company

Sponsor

Country

Therapeutic Area

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

Alnylam Pharmaceuticals

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

U.S.A

Virtual Booth

Digital Content

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypert...

Details:

ALN-AGT01 (zilebesiran) investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen in development for the treatment of hypertension in high unmet need populations.

Lead Product(s): Zilebesiran,Olmesartan Medoxomil

Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT01

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 07, 2024

ASK
US

Upload
your Pipeline Activity

Alnylam Pharmaceuticals

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

U.S.A

Virtual Booth

Digital Content

Roche and Alnylam Report Positive Topline Results from The Phase II Kardia-2 Study in People with Hypertension, Demonstrating Clinically Significant Blood Pressure Reductio...

Details:

ALN-AGT01 (zilebesiran) is an investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen. It is being evaluated in combination with standard of care for the treatment of hypertension.

Lead Product(s): Zilebesiran,Olmesartan Medoxomil

Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT01

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 05, 2024

ASK
US

Upload
your Pipeline Activity

Alnylam Pharmaceuticals

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

U.S.A

Virtual Booth

Digital Content

Roche Enters Partnership with Alnylam to Co-Develop and Co-Commercialise RNAi Therapeutic Zilebesiran to Treat Hypertension in Patients with High Cardiovascular Risk

Details:

Under the partnership, Roche and Alnylam will co-develop and co-commercialise RNAi therapeutic ALN-AGT01 (zilebesiran), an investigational RNAi therapeutic currently in Phase 2 for the treat hypertension in patients with high cardiovascular risk.

Lead Product(s): Zilebesiran,Olmesartan Medoxomil

Therapeutic Area: Cardiology/Vascular Diseases Product Name: ALN-AGT01

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: Undisclosed Upfront Cash: $310.0 million

Deal Type: Partnership July 24, 2023

ASK
US

Upload
your Pipeline Activity

Zydus Lifesciences

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

India

Virtual Booth

Digital Content

Zydus Receives Final Approval from The USFDA for Olmesartan Medoxomil and Hydrochlorothiazide Tablets

Details:

A generic combination is approved consisting of olmesartan medoxomil which blocks the vasoconstrictor effects of angiotensin II in vascular smooth muscle and hydrochlorothiazide is a diuretic that inhibits sodium chloride transport in the distal convoluted tubule.

Lead Product(s): Olmesartan Medoxomil,Hydrochlorothiazide

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Benicar HCT-Generic

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 28, 2023

ASK
US

Upload
your Pipeline Activity

Daiichi Sankyo

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Japan

Virtual Booth

Digital Content

Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the United States, Shifting Focus to Oncology Portfolio

Details:

The agreement outlines a transition period during which Daiichi Sankyo and Cosette will transfer responsibilities for the manufacture and commercialization of Azor, Benicar, Effient and other products, including quality assurance, pharmacovigilance and regulatory matters.

Lead Product(s): Amlodipine,Olmesartan Medoxomil

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Azor

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Cosette Pharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Divestment January 18, 2022

ASK
US

Upload
your Pipeline Activity

Find Clinical Drug Pipeline Developments & Deals for Olmesartan Medoxomil